NCT04626791 - Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 3, 2021

Primary Completion Date

August 3, 2024

Study Completion Date

August 3, 2028

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

DRUG

Bortezomib

Given SC

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

BIOLOGICAL

Rituximab and Hyaluronidase Human

Given IV

Trial Locations (7)

10029

ACTIVE_NOT_RECRUITING

Mount Sinai Hospital, New York

28203

RECRUITING

Carolinas Medical Center/Levine Cancer Institute, Charlotte

53226

WITHDRAWN

Aurora Cancer Care-Milwaukee West, Wauwatosa

55404

WITHDRAWN

Metropolitan-Mount Sinai Medical Center, Minneapolis

70121

WITHDRAWN

Ochsner NCI Community Oncology Research Program, New Orleans

98109

WITHDRAWN

Fred Hutchinson Cancer Research Center, Seattle

98195

RECRUITING

University of Washington Medical Center - Montlake, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER